Show simple item record

dc.rights.licenseCC BY — Creative Commons Attribution
dc.contributor.authorOduah, E.
dc.contributor.authorLinhardt, Robert J.
dc.contributor.authorSharfstein, S.T.
dc.date2016
dc.date.accessioned2022-06-21T18:04:13Z
dc.date.available2022-06-21T18:04:13Z
dc.date.issued2016
dc.identifier.citationHeparin: Past, Present, and Future, E. Oduah, R. J. Linhardt, S. T. Sharfstein, Pharmaceuticals, 9, 38, 2016.
dc.identifier.urihttps://hdl.handle.net/20.500.13015/5090
dc.identifier.urihttps://doi.org/10.3390/ph9030038
dc.descriptionPharmaceuticals, 9, 38
dc.descriptionNote : if this item contains full text it may be a preprint, author manuscript, or a Gold OA copy that permits redistribution with a license such as CC BY. The final version is available through the publisher’s platform.
dc.description.abstractHeparin, the most widely used anticoagulant drug in the world today, remains an animal-derived product with the attendant risks of adulteration and contamination. A contamination crisis in 2007-2008 increased the impetus to provide non-animal-derived sources of heparin, produced under cGMP conditions. In addition, recent studies suggest that heparin may have significant antineoplastic activity, separate and distinct from its anticoagulant activity, while other studies indicate a role for heparin in treating inflammation, infertility, and infectious disease. A variety of strategies have been proposed to produce a bioengineered heparin. In this review, we discuss several of these strategies including microbial production, mammalian cell production, and chemoenzymatic modification. We also propose strategies for creating "designer" heparins and heparan-sulfates with various biochemical and physiological properties.
dc.languageen_US
dc.language.isoENG
dc.publisherMultidisciplinary Digital Publishing Institute (MDPI)
dc.relation.ispartofThe Linhardt Research Labs Online Collection
dc.relation.ispartofRensselaer Polytechnic Institute, Troy, NY
dc.relation.urihttps://harc.rpi.edu/
dc.rightsAttribution 3.0 United States*
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/us/*
dc.subjectBiology
dc.subjectChemistry and chemical biology
dc.subjectChemical and biological engineering
dc.subjectBiomedical engineering
dc.titleHeparin: Past, Present, and Futureen_US
dc.typeArticle
dcterms.accessRightsOpen Access
dcterms.accessRightsA full text version is available in DSpace@RPI
dcterms.isVersionOfhttps://doi.org/10.3390/ph9030038
dc.rights.holderCC BY : this license allows reusers to distribute, remix, adapt, and build upon the material in any medium or format, so long as attribution is given to the creator. The license allows for commercial use. Credit must be given to the authors and the original work must be properly cited.
dc.creator.identifierhttps://orcid.org/0000-0003-2219-5833
dc.relation.departmentThe Linhardt Research Labs.
dc.relation.departmentThe Shirley Ann Jackson, Ph.D. Center for Biotechnology and Interdisciplinary Studies (CBIS)


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record

CC BY — Creative Commons Attribution
Except where otherwise noted, this item's license is described as CC BY — Creative Commons Attribution